N = 49 | |
---|---|
Age, median (IQR) | 67 (50–75) |
Male, n (%) | 36 (73.5) |
Charlson index, n (%) | 2 (1–4) |
Type of infection, n (%) | |
Complicated bloodstream infection | 34 (69.4) |
Uncomplicated bloodstream infection | 15 (30.6) |
Causative organism, n (%) | |
MSSA | 15 (30.6) |
MRSA | 9 (18.4) |
CNS | 17 (34.7) |
E. faecalis | 1 (2) |
E. faecium | 2 (4.1) |
Streptococcus | 2 (4.1) |
Other | 1 (2) |
No isolation | 2 (4.1) |
Days of prior AB therapy, median (IQR) | 8 (0–15) |
Prior antibiotic therapy, n (%) | 46 (93.9) |
Daptomycin | 22 (44.9) |
Ceftriaxone | 10 (20.4) |
Linezolid | 9 (18.4) |
Vancomycin | 11 (22.4) |
Reason for DBV administration, n (%) | |
Facilitate discharge | 38 (77.6) |
Prior treatment failure | 1 (2) |
Toxicity | 2 (4) |
DBV dose, n (%) | |
1000 mg (1 day), 500 mg (8 days) | 14 (28.6) |
1000 mg 1 day | 11 (22.4) |
1500 mg 1 day | 21 (42.9) |
Other | 3 (6.1) |
DBV-covered treatment days (IQR) | 14 (14) |
Clinical cure, n (%) | 49 (100) |
Microbiological cure | |
Follow-up blood cultures, n (%) | 36 (73.5) |
Negative follow-up blood cultures | 35 (97.2) |
Death related to bloodstream infection, n (%) | 0 |
Relapse, n (%) | 0 |
Readmission for different reason | 1 (2) |
Reduction in days of hospital stay (IQR) | 14 (7–14) |
Total reduction, days | 636 |